17 August 2026
Cambridge Nutritional Sciences plc
(the "Company" or "CNSL")
Updated Notice of Results & Investor Presentation via Investor Meet Company
Cambridge Nutritional Sciences plc (AIM: CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces an updated date for the publication of its Audited Results for the year ended 31 March 2026 which will now be Tuesday, 8 September 2026. This delay is due to auditor and Company bandwidth in the audit process. The Board reiterates its expectation that revenue, EBITDA and cash remain in line with market expectations as reported.
Investor Presentation:
On the same day at 14:30 BST, James Cooper (Chief Executive Officer) and Ajay Patel (Chief Financial Officer) will host a live online presentation via the Investor Meet Company ("IMC") platform to discuss the results.
The presentation is open to all existing and potential shareholders. Questions can be submitted in advance via the IMC dashboard up until 09:00 BST on 7 September 2026, or during the live event.
To register for the event and add Cambridge Nutritional Sciences plc to your watchlist, please visit:
https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor
Shareholders who already follow Cambridge Nutritional Sciences plc on the IMC platform will be automatically invited to the presentation.
Contacts:
Cambridge Nutritional Sciences plc | ||
Carolyn Rand, Non-Executive Chair | ||
James Cooper, Chief Executive Officer | ||
Ajay Patel, Chief Financial Officer | ||
Cavendish Capital Markets Limited | Tel: 020 7220 0500 | |
Geoff Nash / Edward Whiley / (Corporate Finance) | ||
Nigel Birks / Harriet Ward (ECM) | ||
About Cambridge Nutritional Sciences plc
Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.